HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive: Other HDAC inhibitors like LBH589 can be combined with Imatinib [83], Nilotinib [10] or LAQ824 to eliminate Imatinib-refractory primary CML cells [83,99].